MiniMed director receives 27,778-share stock grant

MiniMed Group, Inc. director Kevin E. Lofton reported an equity compensation grant of 27,778 shares of Common Stock in the form of restricted stock units.

Rhea-AI Filing Summary

MiniMed Group, Inc. director Kevin E. Lofton reported an equity compensation grant of 27,778 shares of Common Stock in the form of restricted stock units. The award was granted at no cash cost per share and is scheduled to vest on the one-year anniversary of the grant date.

After this grant, Lofton is shown as owning 27,778 shares directly, which include shares to be issued upon future vesting of one or more restricted stock units. This filing reflects a routine compensation-related acquisition rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 27,778 shares

Grant/Award 1 txn

Insider Lofton Kevin E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	27,778	$0.00	$0.00

Holdings After Transaction: Common Stock — 27,778 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units that vest on the one-year anniversary of the grant date.
2. F2. Includes shares to be issued in connection with the vesting of one or more restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MiniMed Group (MMED) report for Kevin E. Lofton?

MiniMed Group reported that director Kevin E. Lofton received an equity grant of 27,778 restricted stock units. These units represent shares of Common Stock that will vest on the one-year anniversary of the grant date, reflecting routine, compensation-based ownership rather than an open-market trade.

How many MiniMed Group (MMED) shares does Kevin E. Lofton hold after this Form 4?

After the reported transaction, Kevin E. Lofton holds 27,778 MiniMed Group Common Stock shares directly. This total includes shares that will be issued in connection with the vesting of one or more restricted stock units, as described in the filing’s footnotes and ownership table details.

Was Kevin E. Lofton’s MiniMed (MMED) stock grant an open-market purchase?

No, Kevin E. Lofton’s MiniMed stock grant was not an open-market purchase. It was coded as a grant or award acquisition at a per-share price of $0.00, indicating compensation-related restricted stock units rather than shares bought on the open market for cash consideration.

When do Kevin E. Lofton’s MiniMed (MMED) restricted stock units vest?

The restricted stock units granted to Kevin E. Lofton are scheduled to vest on the one-year anniversary of the grant date. Upon vesting, the units convert into shares of Common Stock, consistent with the footnote disclosure describing the vesting schedule and future share issuance mechanics.

What does the Form 4 footnote say about MiniMed (MMED) shares included in Lofton’s holdings?

The Form 4 footnote explains that Lofton’s reported holdings include shares to be issued in connection with the vesting of one or more restricted stock units. This clarifies that the disclosed total reflects both current and future issuances tied to his outstanding equity awards.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/11/2026 - 04:31 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lofton Kevin E

(Last) (First) (Middle)

C/O 18000 DEVONSHIRE STREET

(Street)

NORTHRIDGE CA 91325

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiniMed Group, Inc. [ MMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/09/2026		A		27,778(1)	A	$0	27,778(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units that vest on the one-year anniversary of the grant date.

2. Includes shares to be issued in connection with the vesting of one or more restricted stock units.

Remarks:

	/s/ Bryan F. Kelly, attorney-in-fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.